Dravet Syndrome (DS) is a historically severe epileptic and developmental encephalopathy forming uncontrolled seizures with stimuli, other neurological deficits, including cognitive and motor function impairment. This work demonstrates two case studies of infants suffering from DS that are complicated by recurrent infections and developmental delays. Early genetic evaluation, especially SCN1A testing, was important for diagnosis and therapy. Both infants presented periodic prolonged febrile seizures as well, thus exposed to a range of anti-seizure drugs which include Levetiracetam, Sodium Valproate and Topiramate. In addition to this, Cannabidiol (CBD) was included in their regimen and proved effective in term of seizure control where other therapies were not effective. Somnolence, gastrointestinal upset and elevated liver enzyme levels necessitated caution in usage. Also, management of patients involved several disciplines: neurologic, genetic and developmental care as well as control of infections. However, patients were able to achieve some level of stabilization with early interventions such as physiotherapy and nutritional interventions despite the persistent developmental challenges. Based on the unmet clinical needs in controlling seizures in DS disorders, CBD is appropriate, but caring for the patients should be enduring and additional research is needed on the optimal doses in children.
